Home / Transcripts / Precipio, Inc. (PRPO) · November 17, 2025

Precipio, Inc. (PRPO) Earnings Call Transcript

November 17, 2025

NASDAQ US Health Care Health Care Providers and Services earnings 17 min

Earnings Call Speaker Segments

Ilan Danieli executive
#1

Good afternoon, and thanks to everyone for being here today as we go through Precipio's financial and operational results for Q3 of 2025. For Precipio, this quarter represents a genuinely proud milestone; we have, for the first time since the company was founded, posted a positive adjusted EBITDA of almost $500,000, and what may matter even more, we produced more than $250,000 in cash from operations. That goes beyond a financial win; it confirms our long-term strategy, our disciplined execution, and the remarkable commitment of our team. It also sets in motion a shift in how our team approaches things and thinks. If I borrow an analogy from sports, we are transitioning from playing defense to playing offense. Let me offer an illustration of that shift. At this same point last year, management meetings centered on how to get to break-even. How could we grow revenue and hold expenses down, squeezing additional margin dollars from the operations we already had? We held the belief that once financial independence was achieved, we would not only be able to grow the business properly on our own terms, but also meaningfully boost the company's value, and in turn, unlock a great many growth opportunities. Anyone familiar with healthcare, and particularly the diagnostic space, understands that hitting profitability at revenue levels like ours is practically unheard of. Businesses generating 10x our revenue are losing millions of dollars annually while repeatedly raising dilutive capital, and we simply had no desire to be that kind of company; this quarter, management meetings showed a transformation in mindset regarding the way we view growing our business. The discussion shifted entirely; the focus now is entirely on how to put the cash we generate back to work responsibly and strategically so that the growth of our company accelerates further. That sort of transformation occurs only when every area of the business — R&D, sales, operations, finance — is pulling in the same direction. As our consistent performance continues to drive market cap appreciation, we expect this to open many doors, letting us explore numerous avenues for growing the business. Starting in early 2025, as we showed our gradual progress toward this milestone, our share price has reacted, tripling from where the year began. With that financial goal now reached and continued growth ahead of us, we can start adopting a more strategic approach, putting money into our growth and into gaining market share; during today's call, I'll share a few examples of the steps we've taken to position the company for the growth we anticipate and to support the expanding sales funnel we're seeing. I must say, being in this position now, with resources of our own that we direct ourselves, to take this company to the next level, is truly great. First, let me take you through several financial highlights from this quarter and add some detail on a handful of the metrics. Q3 came in at $6.8 million, up 30% year-over-year and 20% quarter-over-quarter. This was another quarter where we achieved double-digit expansion, powered by our Pathology Services Division along with our Products Division. To begin with the Pathology Services Division, the team turned in an outstanding quarter; as it happens, the $2 million monthly record for pathology revenue in July that we discussed on the previous shareholder call proved not to be merely a blip, but instead our new standard. Revenue climbed by about $1 million, which is 20%, moving from $5 million in Q2 up to $6 million in Q3; most of that increase came from new customers choosing Precipio for our services. Our pipeline of additional customers is still robust. A number of them are currently in trial phases, and we anticipate further conversions over the quarters ahead. What's especially gratifying is that we generated this expansion without any meaningful rise in fixed costs. The additional volume was absorbed efficiently by our operations team, producing ongoing gross margin gains, which went up from 43% to 46% during this quarter. After meeting with a new oncology group, one of our sales reps came back and shared how successfully we had won a new customer. According to her, "They're switching over from one of the large national labs because they're just tired of being treated like another number." We hear that same theme again and again. Our nimbleness and tailored service are allowing us to win customers away from far bigger competitors as we help them in their effort to deliver the best care to their patients. Luckily, we've built not only the infrastructure required to provide this level of service at scale. Even more important, we've cultivated a culture and mindset that lets us give a customer genuinely personalized attention. It's our culture that converts that scalability into lasting success. That culture is characterized by accountability, collaboration, and customer empathy — attributes that let us grow while preserving outstanding service and at the same time expanding our gross margins. Now, turning to our Products Division. Our Products Division achieved 16% quarter-over-quarter growth, rising from approximately $620,000 in Q2 to $720,000 in Q3. This increase came mainly from greater utilization by existing customers and from the launch of new panels that broadened our customers' purchases. We also set the stage for several new customers who will go live between this quarter and the next, positioning the division for continued growth. One longtime customer recently went from using just one of our panels to three and soon to be four; they noted that our platform dramatically shortened their turnaround time, reduced the tests they were sending out, and had a favorable effect on their bottom line; that's precisely the kind of deepening engagement that fuels our growth. On the distribution side, we're seeing an exciting uptick in activity, which has led to the expansion of our distributor-generated sales funnel. First, we've increased our interaction and further built relationships with distributor sales reps. Next, we've identified more qualified targeted customers. Third, we've been brought in to present our value proposition to these customers. To wrap up, those conversations have led us to put forward proposals and build out an onboarding plan alongside customers — in short, our distributor business model is beginning to deliver results. All of this signals a dependable recurring revenue foundation that keeps growing each quarter. We still hold the view that while internal direct sales remain the source of most of our business at present, the route to genuinely scalable growth lies in tapping into our distributors' network, and that model is starting to pay off. Turning to gross margins. On the whole, gross margins ticked up modestly, from 43% to 44%, and we anticipate that consistent upward trajectory will carry on as both divisions expand and scale. Let me spend a moment on the Products Division's operations, since I believe it's worth walking through what's driving the temporary drop in gross margins, from 44% last quarter to 30% this quarter. Production inefficiencies or elevated raw material costs did not bring about this shift. It stems from two fairly small strategic investments that matter for our next phase of growth. To begin, we enlarged our lab space.

Ilan Danieli executive
#2

For a number of years, while our clinical Pathology Services operation expanded — bear in mind that during the last 2 years we've doubled the number of cases we handle — the amount of lab space we occupy stayed unchanged even as we processed all that volume. As our Products Division also expanded, it became necessary to create a separate area of lab space devoted to production, rather than continuing with a single lab space that the two divisions shared. A key principle behind manufacturing a high-quality product is that the space used for clinical services and the space used for product production genuinely ought to be kept apart. From the day our company began, we've had one floor in our building, and during Q3 of this year, an opportunity arose to grow by taking part of the floor directly above us; that growth let us correctly divide the two sides of our business, which improves efficiency, quality, and growth. The added yearly rent for this extra space comes to roughly $120,000 per year, and this quarter marked the first time that higher cost flowed through the P&L, which pushed margins down. Even so, if you run the numbers, given the extra quarterly expense of the new space of about $30,000, a revenue gain of $100,000, such as the one we posted this quarter, brings us straight back up to a gross margin in the mid-40s. Next, we added another technical support specialist, whose job is to assist customers in onboarding more quickly and in beginning to generate revenue sooner. Something we've noticed, and we've talked about this previously, is that customer laboratories generally operate beyond capacity, lack sufficient staff, and face personnel limitations all the time. They're occupied running their routine clinical samples, which is as it should be, but as a result, efforts like validating and introducing new assays frequently get pushed to the back burner. When our technical specialists are present on-site with the customer, it helps steer greater attention toward validating our product. Our specialists are able to offer considerable guidance and support. We don't perform the work in their place, but we can definitely assist them in keeping things moving and in cutting down the timeline to going live. The return on investment from speeding up revenue relative to what the specialist costs is obvious. This new technical specialist started last quarter, and although he has devoted most of his time to training, he also managed to spend some time with a customer, helping speed up their onboarding of 2 new panels, which will produce an incremental quarterly gain of roughly $50,000 a quarter. These 2 added costs will affect margins for a while, yet they are precisely what we require to back the next $50 million of yearly revenue growth. In the same way that the margin dropped somewhat because of these essential fixed costs, it will rebound just as fast as revenue scales up. With the new lab space plus that support specialist, we're set up to scale without much friction, and over the coming 12 to 24 months we don't anticipate taking on more overhead. Meanwhile, our Pathology Services Division continues to see margins rise — they've moved from 43% to 46% — reflecting the benefits of volume leverage and the smart capacity investments we made earlier. Overall, we're confident that companywide gross margin will continue to increase and exceed 50% by mid-2026, as both divisions are driving higher revenues from the infrastructure they already have in place. Adjusted EBITDA for Q3 landed at $469,000, versus $100,000 during the same period a year earlier, and versus a $78,000 loss in the prior quarter, Q2 2025. That works out to a swing exceeding $500,000 within a single quarter, and it factors in extra spending on facilities and personnel meant to drive growth. Just as significant, we produced $285,000 of cash from operations, against a cash burn of $148,000 during the prior quarter, Q2. That represents a $433,000 favorable swing in operating cash flow. Only two months remain before we finish paying back Change Healthcare in full, which runs $240,000 each quarter, so beginning in Q1 2026, cash our operations generate will remain with the company; these results demonstrate that we have passed a significant milestone. First, running our business no longer requires outside capital, and we can grow organically. We have become a self-sustaining business, able to fuel our own growth. Second, as our market cap grows to align with our financials, fresh strategic opportunities could emerge, and with a larger market cap, financing them through outside capital becomes easier. No matter how things play out, I can tell you from my vantage point that this business will never need to go out and raise money just to fund its burn — and honestly, that's a fantastic spot to be in. Looking ahead to finishing up 2025 and moving into the year after, we know exactly what we're focused on. One, continue pushing double-digit growth in both divisions. Two, widen margins as we get bigger. Three, put our cash back into growth efforts that make our market position stronger. Four, turn the company's operational and financial wins into better liquidity and a higher share price by doing more activities aimed at investors. Being financially self-sufficient gives us so many options — whether that's teaming up with partners strategically, launching new and innovative offerings, or putting money into our operations so we can move faster and stay ahead. Getting to this point took enormous discipline and creativity from our teams, and our goal is to keep that momentum going. Something I really appreciate about this company is the way our mission and our metrics reinforce each other. A pathologist here recently shared something with me: "Every time we get a diagnosis right, that's a patient whose correct treatment starts faster." Hearing that reminds me why this growth is about more than just the numbers. I'd like to pause and express my gratitude to each and every person on the Precipio team. This accomplishment belongs to all of you. The people on our sales side go after the market the way a hawk goes after prey — sharp, quick, and always taking business away from rivals. Everyone else pairs an endless commitment to looking after patients with careful handling of operations and money, which keeps the company running smoothly. They are the ones who earned this. I also want to thank our shareholders — you were patient and remained with us while the path was rough. I hope all of you can tell how deeply determined we are to convert the commercial and financial progress of this business into worth for stockholders. From where I sit, this is really just the beginning. I appreciate the confidence and backing you keep giving us. May your holiday time be wonderful and your new year be joyful — we'll speak once more in 2026. Enjoy your evening. Thanks so much.

Operator operator
#3

That brings this call to a close. We appreciate everyone joining us for today's presentation. You're welcome to hang up at this point.

For developers and AI pipelines

Programmatic access to Precipio, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.